New Oral Anticoagulants in Antiphospholipid Syndrome Treatment

doi:10.5083/ejcm

Contents

Abstract
Keywords

Download XML

359 Views

224 Downloads

Share this article

Research Article | Volume 11 Issue :4 (, 2021) | Pages 13 - 20

New Oral Anticoagulants in Antiphospholipid Syndrome Treatment

Under a Creative Commons license

Open Access

DOI : 10.5083/ejcm

Published

Dec. 25, 2021

Abstract

morbidity in the presence of persistent antiphospholipid antibodies. Current therapeutic recommendations for thrombosis prevention in patients with APS are limited to anticoagulation with Vitamin K Antagonists (VKA) or heparins and to anti-platelet aggregating agents. Maintaining optimized anticoagulation to prevent recurrent thrombosis or bleeding remains a therapeutic challenge. Direct Oral Anticoagulants (DOACs) DOACs have been approved to prevent recurrent thrombotic events in different prothrombotic conditions, such as non- valvular atrial fibrillation, deep vein thrombosis still aim the same target and thromboprophylaxis after elective orthopedic surgery.

Keywords

DOACs

VKAs

APS

European Journal of Cardiovascular Medicine

Download PDF